NASDAQ: EVAXEvaxion Biotech A Stock
$1.55-0.06 (-3.73%)
Updated May 26, 2023
EVAX Price
$1.55
Fair Value Price
$2.32
Market Cap
$37.42M
52 Week Low
$0.92
52 Week High
$3.52
P/E
-1.58x
P/B
4.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.65
Operating Cash Flow
-$26M
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVAX Overview
Evaxion Biotech A/S develops novel immunotherapies to treat various cancers, bacterial diseases, and viral infections suing proprietary AI platforms (PIONEER, EDEN, and RAVENTM). The company's drug candidates include EVX-01, EVX-02, and EVX-03. Evaxion Biotech A/S has collaboration agreements with the National Center at Herlev Hospital, the Department of Health Technology at Danish Technical University, and other institutions. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVAX ($1.55) is undervalued by 33.16% relative to our estimate of its Fair Value price of $2.32 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EVAX ($1.55) is significantly undervalued by 33.16% relative to our estimate of its Fair Value price of $2.32 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EVAX due diligence checks available for Premium users.
Be the first to know about important EVAX news, forecast changes, insider trades & much more!
EVAX News
Valuation
EVAX fair value
Fair Value of EVAX stock based on Discounted Cash Flow (DCF)
Price
$1.55
Fair Value
$2.32
Undervalued by
33.16%
EVAX ($1.55) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EVAX ($1.55) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.58x
Industry
11.86x
Market
54.23x
EVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.51x
Industry
5.18x
EVAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVAX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
EVAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.0M
Liabilities
$13.7M
Debt to equity
1.65
EVAX's short-term assets ($16.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVAX's short-term assets ($16.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVAX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
EVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVAX vs Biotech Stocks
Evaxion Biotech A Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.